pulmonary hypertension

Pulmonary arterial hypertension is a rare, progressive vasculopathy leading to right heart failure and high mortality without aggressive treatment. Endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclase stimulators, and prostanoids form the basis of an evidence-based combination treatment strategy. Sotatercept, a first-in-class activin signalling inhibitor, has demonstrated significant benefits in the pivotal STELLAR trial.